Loading stock data…
UroGen Pharma Ltd (URGN)
$36.07+1.53 (+4.43%)
After Hours$36.07+0.00 (+0.00%)· Last close Jun 29
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
UroGen Pharma Ltd. in the Healthcare sector is trading at $36.07 with a market capitalization of $1.5B. Wall Street consensus targets $36.88 (8 analysts), implying a +2.2% move over the next 12 months. The stock is currently near its 52-week high of $36.67, remaining 59.9% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $50.96M↑ | $37.84M↑ | $27.48M↑ | $24.21M↑ | $20.25M |
| Gross Profit | $46.82M↑ | $34.55M↑ | $24.20M↑ | $20.66M↑ | $17.92M |
| Operating Income | -$20.26M↓ | -$19.11M↑ | -$27.39M↑ | -$41.45M↓ | -$36.91M |
| Net Income | -$23.57M↑ | -$26.36M↑ | -$33.35M↑ | -$49.94M↓ | -$43.84M |
Peer Comparison
JNJUNHPFE
Fundamentals
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technolog...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.48B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
107.22%
Volume
Today's trading volume
550,588
Recent News
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
Focused on urinary tract cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains.
Will UroGen’s Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative?
In June 2026, UroGen Pharma Ltd. and UroGen Pharma Inc. announced a settlement and license agreement with Teva Pharmaceuticals resolving U.S. patent litigation over Jelmyto, granting Teva a non-exclusive license to sell a generic version from September 15, 2030, subject to FDA approval and regulatory review of the agreement. This settlement clarifies the expected timing of potential generic entry for Jelmyto, reducing legal uncertainty around one of UroGen’s key products. With the Jelmyto...
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.
How UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) Investors
In May 2026, UroGen Pharma reported that UGN-103 achieved a 94.5% six-month durability of response in the Phase 3 UTOPIA trial for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, with data aligning closely to its already approved bladder cancer therapy ZUSDURI. A key angle for investors is that UGN-103 is designed to build on ZUSDURI’s existing clinical foundation with a more streamlined manufacturing process, simplified reconstitution, and intellectual property...